Fig. 2From: Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial28-day ACM in ceftolozane/tazobactam- or meropenem-treated patients by renal function. ACM all-cause mortality, ARC augmented renal clearance, ITT intention-to-treat, mITT microbiologic intention-to-treatBack to article page